期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 55, 期 12, 页码 5851-5858出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm3002795
关键词
-
资金
- Medicines for Malaria Venture
- Australian Research Council [FT0991213, LE0668477, LE0237908]
- Australian Research Council [LE0237908, LE0668477, FT0991213] Funding Source: Australian Research Council
A new bispyrroloiminoquinone alkaloid, tsitsikammamine C (1), displayed potent in vitro antimalarial activity with IC50 values of 13 and 18 nM against chloroquine-sensitive (3D7) and chloroquine-resistant (Dd2) Plasmodium falciparum, respectively. Tsitsikammamine C (1) displayed selectivity indices of >200 against HEK293 cells and inhibited both ring and trophozoite stages of the malaria parasite life cycle. Previously reported compounds makaluvamines J (2), G (3), L (4), K (5) and damirones A (6) and B (7) were also isolated from the same marine sponge (Zyzzya sp.). Compounds 2-4 displayed potent growth inhibitory activity (IC50 < 100 nM) against both P. falciparum lines and only moderate c-ytotoxicity against HEK293 cells (IC50 = 1-4 mu M). Makaluvamine G (3) was not toxic to mice and suppressed parasite growth in P. berghei infected mice following subcutaneous administration at 8 mg kg(-1) day(-1).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据